Understanding treatment
with VYXEOS

Download this informational guide to learn more about
acute myeloid leukemia and treatment with VYXEOS.

This is John's story.

John shares his journey, from being diagnosed with AML-MRC to his personal experience with VYXEOS.

Watch now

Download this informational guide for patients and caregivers

What is VYXEOS?

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is an intravenous (IV) chemotherapy used for the treatment of adults with certain types of newly-diagnosed acute myeloid leukemia (AML). These types include patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders (also called AML with myelodysplasia-related changes, AML-MRC).

Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.

Important Safety Information